1. Vidal Giné C, Ventura Vilamala M, Fornís Espinosa I, Gil Lladanosa C, Calzada Álvarez N, Fitó Fruitós A, et al. Crystals and tablets in the Spanish ecstasy market 2000–2014: are they the same or different in terms of purity and adulteration? Forensic Sci Int. 2016;263:164–8.
2. Betzler F, Heinz A, Köhler S. [Synthetic drugs: an overview of important and newly emerging substances]. Fortschr Neurol Psychiatr. 2016;84(11):690–8.
3. Saleemi S, Pennybaker SJ, Wooldridge M, Johnson MW. Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol. 2017;31(8):1056–60.
4. Barratt MJ, Bruno R, Ezard N, Ritter A. Pill testing or drug checking in Australia: acceptability of service design features. Drug Alcohol Rev. 2018;37(2):226–36.
5. Brunt TM, Nagy C, Bücheli A, Martins D, Ugarte M, Beduwe C, et al. Drug testing in Europe: monitoring results of the trans European drug information (TEDI) project. Drug Test Anal. 2017;9(2):188–98.